### PEST AVAILABLE COPY

OT 18 2005

**DRAWINGS** 

1/29

Fig. 1
Inhibition effects of anti-HIV agents of the primary processed matter on the syncytium formation of non-infected cells co-cultured with infected cells




Fig. 1b
Inhibition effects of anti-HIV agents of the present invention on the syncytium formation of non-infected cells co-cultured with infected cells





Fig. 2
Inhibition effects of anti-HIV agents of the primary processed matter on HIV production by PHA-stimulated peripheral blood mononuclear cells that were made to be newly infected.







Fig. 2b
Inhibition effects of anti-HIV agents of the present invention on HIV production by PHA-stimulated peripheral blood mononuclear cells that were made to be newly infected.







Fig. 3

Number of viable cells







Fig. 3b

#### Number of viable cells







Fig. 4

#### ELISA test for HIV P24 antigen yield






Fig. 4b

ELISA test for HIV P24 antigen yield






Fig. 5
Anti-HIV effects of pretreated PHA-stimulated peripheral blood mononuclear cells with Kabanoanatake

#### A The effects of pretreatment HIV with Kabanoanatake




#### B The effects of target cell pretreatment with Kabanoanatake



\* The anti-HIV agents were prepared in PBS solution at the concentration of 3.5 mg/ml.

Fig. 6

A The effects of pretreatment of target cells with Kabanoanatake



Pretreatment time of target cells with Kabanoanatake (hours)

B The effects of addition of Kabanoanatake in various incubation times after target cells pretreatment with anti-HIV agents for approximately one hour





Fig. 6

A-2 The effects of pretreatment of target cells with Kabanoanatake



Pretreatment time of target cells with Kabanoanatake (hours)

## B-2 The effects of addition of Kabanoanatake in various incubation times after target cells pretreatment with anti-HIV agents for approximately one hour






Fig. 7
Inhibition effects of anti-HIV agents of the primary processed matter on the syncytium formation of non-infected cells co-cultured with infected cells




<sup>\*</sup> The anti-HIV agents were prepared at the concentration of 3.56 mg/ml.

Fig. 7b
Inhibition effects of anti-HIV agents of the present invention on the syncytium formation of non-infected cells co-cultured with infected cells



<sup>\*</sup> The anti-HIV agents were prepared at the concentration of 3.56 mg/ml.

Fig.8






Fig.8b




Fig. 9
Inhibition effects of various Kabanoanatake of the primary processed matter on the syncytium formation of non-infected cells co-cultured with infected cells




Fig. 9b
Inhibition effects of various Kabanoanatake of the present invention on the syncytium formation of non-infected cells co-cultured with infected cells




Fig. 10

#### Report of separation of HIV

July, 18th, 1995

Day of receipt of samples: June, 14th, 1995

#### (1) Tissue culture infectious dose (TCID)

Total TCID (/ ml)	0
Cell TCID $(/1 \times 10^6)$	0
Plasma TCID (/ ml)	0
Cytopathic effect	0

#### (2) Anti-HIV antibody in plasma by western blotting methods.

gp160	gp120	p65	p55	p51	gp41-43	p32	p24	p18	p15
(env)	(env)	(pol)	(gag)	(pol)	(env)	(pol)	(gag)	(gag)	(gag)
++	++	++	++	++	++	++	++	++	++

#### (3) Host range index

(Correspondence column) The virus was not isolated.

(Annotation) Also, in a blood test after three months for the same patient, TCID value was excellent (zero).

**Fig. 10b** 

#### Report of separation of HIV

August, 1<sup>st</sup>, 1998

Day of receipt of samples: June, 14th, 1995

#### (1) Tissue culture infectious dose (TCID)


Total TCID (/ ml)	0
Cell TCID (/1×10°)	0
Plasma TCID (/ ml)	0
Cytopathic effect	


#### (2) Anti-HIV antibody in plasma by western blotting methods.


gp160	gp120	p65	p55	p51	gp41-43	p32	p24	p18	p15
(env)	(env)	(pol)	(gag)	(pol)	(env)	(pol)	(gag)	(gag)	(gag)
++	++	++	++	++	++	++	++	++	++


#### (3) Host range index


(Correspondence column) The virus was not isolated.































Fig. 22 The values of perfect HIV inhibition activity (100%) on the 110th day of a liquid culture of Kabanoanatake hyphae, A to E, at the ideal temperature for culture of  $25^{\circ}$ C








Fig. 25
Incident rate of papillomas, using the 2-stage carcinogenesis model with mouse skin (average number per mouse)





Fig. 26

The carcinogenetic promotion suppression effects of Compound 1, using the 2-stage carcinogenesis model with mouse skin (percentage)



# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

#### BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
□ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
□ FADED TEXT OR DRAWING
□ BLURRED OR ILLEGIBLE TEXT OR DRAWING
□ SKEWED/SLANTED IMAGES
□ COLOR OR BLACK AND WHITE PHOTOGRAPHS
□ GRAY SCALE DOCUMENTS
□ LINES OR MARKS ON ORIGINAL DOCUMENT
□ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

#### IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.